March 24, 2020 -- DiaCarta said it has filed an emergency use authorization (EUA) application for its QuantiVirus SARS-CoV-2 test with the U.S. Food and Drug Administration. The test has also received the CE Mark in Europe.
The company noted that it has validated the novel coronavirus/COVID-19 diagnostic test in its own CLIA-certified lab in Richmond, CA, to provide testing services for healthcare providers and patients. Based on real-time polymerase chain reaction (PCR) technology, the IVD test is designed to specifically detect SARS-CoV-2 viral DNA extracted from nasopharyngeal swabs, oropharyngeal swabs, and sputum from patients suspected of being infected, according to DiaCarta.
The assay targets three genes of SARS-CoV-2: N, Orf1ab, and E. In studies, the test demonstrated 96.7% sensitivity and 100% specificity, with no cross-reaction to different types of non-SARS-CoV-2 species, DiaCarta said.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current